Exenatide inhibits β-cell apoptosis by decreasing thioredoxin-interacting protein
- 4 August 2006
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 346 (3), 1067-1074
- https://doi.org/10.1016/j.bbrc.2006.06.027
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a SulfonylureaDiabetes Care, 2005
- Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 DiabetesDiabetes Care, 2005
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Role of Endogenous Glucagon-Like Peptide-1 in Islet Regeneration After Partial PancreatectomyDiabetes, 2003
- Exendin-4 as a Stimulator of Rat Insulin I Gene Promoter Activity via bZIP/CRE Interactions Sensitive to Serine/Threonine Protein Kinase Inhibitor Ro 31-8220Endocrinology, 2002
- Glucagon-like Peptide 1 Increases Glucose-Dependent Activity of the Homeoprotein IDX-1 Transactivating Domain in Pancreatic β-CellsBiochemical and Biophysical Research Communications, 2000
- Effects of glucagon‐like peptide 1 (7–36 amide) on whole‐body protein metabolism in healthy manEuropean Journal of Clinical Investigation, 1997
- Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patientsDiabetologia, 1993
- Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.Proceedings of the National Academy of Sciences of the United States of America, 1992
- Glucagon-like peptide-1(7–37)/(7–36)amide is a new incretinMolecular and Cellular Endocrinology, 1992